Yoshiyuki Yamakawa
Direttore/Membro del Consiglio presso D. WESTERN THERAPEUTICS INSTITUTE, INC.
Provenienza dei contatti di primo grado di Yoshiyuki Yamakawa
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Medical Specialties | 7 | |
| Public Company | Pharmaceuticals: Major | 4 | |
Hibiki Partners Co., Ltd.
1
| Private Company | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Yoshiyuki Yamakawa tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| Keio University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Tokyo | College/University | Doctorate Degree | |
| Tohoku University | College/University | Graduate Degree | |
| Yokohama National University | College/University | Undergraduate Degree | |
| ACUCELA INC | Pharmaceuticals: Major | Director/Board Member | |
BioServe Biotechnologies Ltd.
 BioServe Biotechnologies Ltd. BiotechnologyHealth Technology BioServe Biotechnologies Ltd. provides genomics products and services. It offers DNA, RNA extractions, genotyping, real time PCR and molecular diagnostic testing services. The company was founded by Ramakrishna Modali and Robert Skurla in 1989 and is headquartered in Beltsville, MD. | Biotechnology | Chairman Director/Board Member | |
SanBio, Inc.
 SanBio, Inc. Medical/Nursing ServicesHealth Services SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA. | Medical/Nursing Services | Director/Board Member | |
Biopta Ltd.
 Biopta Ltd. Miscellaneous Commercial ServicesCommercial Services Biopta Ltd. provides biological research and human tissues in drug development. It conducts research on the effect of drug activity prior to clinical trials using fresh human tissues. The firm engages in the use of functional human tissue to predict drug activity prior to clinical trials. It provides lab services, comparative pharmacology, clinical biopsies, in vitro and ex vivo techniques, and customized services, as well as cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary related services. The company was founded by David Bunton and Chris Hillier and in 2002 and is headquartered in Glasgow, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
| University of Tsukuba | College/University | Undergraduate Degree | |
Marunouchi Capital Co., Ltd.
 Marunouchi Capital Co., Ltd. Investment ManagersFinance Marunouchi Capital Co., Ltd. (Marunouchi Capital) is a private equity firm headquartered in Tokyo, Japan. The firm was founded in 2008 by Mitsubishi Corp. and Mitsubishi UFJ Securities Co., Ltd. | Investment Managers | Private Equity Investor | |
| McKinsey & Co. (Japan) | Corporate Officer/Principal | ||
| Mie University | College/University | Corporate Officer/Principal | |
| CYFUSE BIOMEDICAL K.K. | Biotechnology | Chief Executive Officer | |
ReproCELL USA, Inc.
 ReproCELL USA, Inc. Medical/Nursing ServicesHealth Services ReproCELL USA, Inc. is based in Beltsville, MD. Part of ReproCELL, Inc., ReproCELL USA, Inc. is a company that engages in iPS cell research business. | Medical/Nursing Services | Director/Board Member Chairman Director/Board Member | |
RC Partners, Inc.
 RC Partners, Inc. Investment ManagersFinance RC Partners, Inc. engages in the operation and management of investment funds. The company was founded on February 12, 2014 and is headquartered in Yokohama, Japan. | Investment Managers | Director/Board Member Director/Board Member | |
| RYUKA IP Law Firm | Corporate Officer/Principal | ||
Stemgent, Inc. /New/
 Stemgent, Inc. /New/ BiotechnologyHealth Technology Stemgent, Inc. develops technology and application solutions for the advancement of stem cell research. The company was founded in 2008 and is headquartered in Lexington, MA. | Biotechnology | Chairman | |
| KOINOBORI Associate, Inc. | Comptroller/Controller/Auditor | ||
| KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
ReproCELL Europe Ltd.
 ReproCELL Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Part of ReproCELL, Inc., ReproCELL Europe Ltd. is a British company that specializes in providing solutions for translating scientific discoveries into therapies. The company is based in Glasgow, UK. The company's expertise lies in human tissue and stem cells, and they offer consultation services to researchers facing challenges in their research. David C. Bunton has been the CEO of the company since 2017. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Japan Innovative Therapeutics, Inc.
 Japan Innovative Therapeutics, Inc. BiotechnologyHealth Technology Part of D. Western Therapeutics Institute, Inc., Japan Innovative Therapeutics, Inc. develops and manufactures pharmaceutical products. The company is based in Nagoya City, Japan. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| SIGNPOST CORPORATION | Medical/Nursing Services | Director/Board Member | |
Repro Curato KK
 Repro Curato KK Medical DistributorsDistribution Services Part of Curato Japan KK, Repro Curato KK is a Japanese company that distributes cosmetics, hair materials, and beauty products. The company is based in Tokyo, Japan. The company was founded in 2016. Repro Curato KK was acquired by Curato Japan KK on July 16, 2021. | Medical Distributors | Director/Board Member | |
| MAGiQ Therapeutics KK | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Giappone | 18 |
| Stati Uniti | 7 |
| Regno Unito | 4 |
Settori
| Health Technology | 9 |
| Consumer Services | 7 |
| Health Services | 4 |
| Commercial Services | 3 |
| Finance | 3 |
Posizioni
| Director/Board Member | 29 |
| Chairman | 9 |
| Corporate Officer/Principal | 6 |
| Chief Administrative Officer | 5 |
| Investor Relations Contact | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Yoshiyuki Yamakawa
- Connessioni Società
